Oxygent


Also found in: Wikipedia.

Oxygent

A perflubron-based synthetic blood substitute which, while it was more effective than Fluosol in transporting O2, nonetheless failed in clinical trials and is not FDA-approved for use in humans.
References in periodicals archive ?
New Alliance Pharmaceuticals is holder of an exclusive licence for perfluorocarbon product Oxygent, whose extensive clinical history will earn Sanguine a leading position in oxygen therapy research and development, according to Sanguine's president, Frank Marra.
New Alliance PharmaceuticalsA is holder ofA an exclusive licence for perfluorocarbon product Oxygent, whose extensive clinical history will earn Sanguine a leading position in oxygen therapy research and development, according to Sanguine's president, Frank Marra.
New Alliance reportedly holds an exclusive license for Oxygent, the most clinically advanced perfluorocarbon (PFC) product in the world, with 20 clinical studies and ~250 preclinical studies already completed.
Gilderod HR, Adams P (1983) Diurnal variations in the oxygent content and acid requement of recirculating nutrients solutions and it the uptake of water and potassium by cucumber and tomato plants.
Alliance is developing Oxygent as an intravascular oxygen therapeutic, based on its proprietary PFC and surfactant technologies.
Oxygent is being developed by Alliance in the United States, Canada, and Europe in conjunction with Baxter.
We unfortunately have to take a little time out here in our clinical development before we forge ahead, but this is a huge market that's not going away," says Peter Keipert, director of Oxygent development at Alliance.
Oxygent is being developed in the United States, Canada, and Europe in conjunction with Baxter Healthcare Corporation.
Oxygent can be used during surgical operations and clinical trials are currently underway for this substitute.
Oxygent has been developed by the Alliance Pharmaceutical Corporation of San Diego, under the direction of molecular chemist Jean Reiss, a pioneer in artificial blood research.
Ltd ("IL YANG") announced the signing of a Licensing, Development and Marketing Agreement ("Agreement") between PFC Therapeutics and IL YANG, granting IL YANG exclusive rights to distribute and commercialize Oxygent in South Korea.
Characterization and mechamism of side-effects of Oxygent HT in swine.